Home > Resources > Whitepapers > First Things First: Primary Cells in Research

First Things First: Primary Cells in Research

September 25, 2018

Primary cells are collected directly from living tissues, and as such, more closely resemble in vivo cells from a genetic and physiological perspective. This feature makes primary cells a treasure trove of potential for investigating in vivo mechanisms, responses, and pathologies. To use primary cells effectively, researchers have to contend with challenges not present when using immortalized cell lines. How do I extract only the cells I want? How long do primary cells live? How can I avoid phenotype drift? Do my cells need a certain spatial alignment?

Spotlight

PatientSafe Solutions

PatientSafe Solutions helps care teams communicate and work together reliably and efficiently through a mobile platform that unites clinical communication with workflows in one application, on one device. PatientTouch delivers secure messages, voice calls, critical alerts and nurse calls to a unified inbox prioritized for each care team member. The platform extends to include clinical workflows like rounding, specimen collection, sepsis and nursing documentation. Deeply integrated with the EMR, clinical, and directory systems, PatientTouch provides real-time patient, clinical and care team context for more efficient care collaboration and decision making. For more than a decade, PatientTouch has helped clinicians both in and outside the hospital streamline care delivery, increase quality and lower costs. For more information, please visit patientsafesolutions.com.

OTHER WHITEPAPERS

Vaccine and Biologics Development in an Emerging Post Pandemic Landscape

whitePaper | September 20, 2022

It is clear within the global health science industry that analytical biosafety testing and advances in developing scientific technologies will play an important role in drug development’s response to the next pandemic.

Are Nitrosamines a Concern for Biologic Manufacturers?

whitePaper | March 30, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk.

Bold Goals for U.S. Biotechnology and Biomanufacturing

whitePaper | March 22, 2023

The world is on the cusp of an industrial revolution fueled by biotechnology and biomanufacturing. Emerging biological technologies are and will continue to transform the foundation of our physical world – everything from clothing, to plastics, to fuels, to concrete.

Asia Pacific – Clinical trial landscape

whitePaper | November 28, 2022

The Asia-Pacific area is home to around two thirds of the world’s population and has a wide range of cultural, political, economic, and other factors that affect vaccine development, use, and registration.

Antibodies to Viral Vectors Responding to Demands toSimplify Progress in Bioprocessing

whitePaper | March 16, 2023

Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.

Gene and cell therapy analytical and development methods

whitePaper | April 20, 2023

In the three decades that have passed since the approval of the first gene therapy in 1990, these revolutionary medicines have changed the lives of patients all over the world1.